antithrombin

(redirected from ATryn)
Also found in: Medical, Encyclopedia.

antithrombin

(ˌæntɪˈθrɒmbɪn)
n
biochem a substance that counteracts the action of thrombin, preventing the formation of blood clots
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
References in periodicals archive ?
The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing services of ant thrombin products such as Antithrombin III, ATryn, and Antithrombin Gama and others as well as new entrants planning to enter this market.
As part of their visit, the delegates got acquainted on-site with operation of SMEs in food and light industries including Mogol Wool LLC and Atryn Shim LLC, TESO Group, and OB Plastic LLC.
(43) In 2009, FDA approved ATryn, the first time that it had approved a drug produced in a GE animal; (44) ATryn treats a rare blood-clotting disorder.
It was reported yesterday that the contract has been signed for the Canadian rights for ATryn and PHOTOFRIN (porfimer sodium), two pharmaceutical products approved for sale in multiple jurisdictions.
The drug ATRyn is from transgenic goat's milk; it is an anticoagulant used to reduce blood clots in childbirth and surgery (Erickson, 2009).
The project in Charlton represents the first major expansion for rEVO since 2009 when it lauched sales of ATryn for patients with an inherited deficiency in the anti-clotting agent antithrombin III.
In the practice known as "pharming," animals are genetically modified to give milk, meat or blood from which medicines are manufactured, as when genetically modified goats produce milk containing a blood-thinning drug called ATryn. Research laboratories use GM mice to seek cures for diseases.
As well, we have made progress towards our goal of improving the profitability of ATryn, with the recently announced return of U.S.
for ATryn, an anticoagulant used to prevent blood clots among patients with hereditary antithrombin deficiency, a rare disease.
ATryn, a recombinant form of human antithrombin developed by GTC Biotherapeutics, was approved by the FDA for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
GTC Biotherapeutics and Ovation Pharamaceuticals received approval from the FDA for ATryn (Antithrombin [Recombinant]) for the prevention of peri-operative and peripartum thromboembolic events in hereditary anthithrombin deficient patients.
The drug, anti-clotting therapy Atryn, is an intravenous therapy made using a human protein gathered from female goats specially bred to produce it in their milk.